Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,883 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06509126RecruitingPhase 3
Panitumumab with Chemo: Continuous or Intermittent for Advanced CRC
This trial compares giving panitumumab plus FOLFIRI (two chemotherapy drugs) either continuously or with breaks, as a first treatment for left-sided colorectal cancer that has spread. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and haven't had treatments for advanced disease before.
NaplesAges 18–100 - NCT07195513Recruiting
Helping advanced cancer patients connect to palliative care via electronic reporting
This trial uses electronic surveys to identify symptoms and unmet needs in people with advanced cancer, then connects them to palliative care services. It aims to improve quality of life by making sure patients get the extra support they need.
Lebanon, New HampshireAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT07223372Recruiting
Study on male hormone blocking drugs for prostate cancer in Australia
This study looks at how certain drugs (darolutamide, enzalutamide, apalutamide, or abiraterone) that block male hormones are used to treat men with prostate cancer that has spread. It aims to understand real-world treatment patterns in Australia.
Pymble, New South WalesAges 18 years+ - NCT06941857RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced pancreatic cancer
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
Baltimore, MarylandAges 18 years+ - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+ - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT07766018RecruitingPhase 2
Elacestrant for advanced or metastatic breast cancer
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
IseharaAges 18 years+ - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT06458413RecruitingPhase 2
Utidelone plus capecitabine for metastatic breast cancer
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Zhengzhou, HenanAges 18–70 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06591650RecruitingPhase 2
Combination therapy for advanced gallbladder cancer
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06962137RecruitingPhase 2
Zolbetuximab plus two chemos for CLDN18.2-positive stomach cancer
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
AntwerpAges 18 years+ - NCT07743944Recruiting
Breast cancer second-line treatment patterns in China
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
Nanjing, JiangsuAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07525206RecruitingPhase 3
New drug combination versus standard treatment for advanced colorectal cancer
This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.
East Brunswick, New JerseyAges 18 years+ - NCT06121453Recruiting
Adherence support for metastatic breast cancer patients
This study tests a program to help people with metastatic breast cancer take their endocrine therapy, CDK4/6 inhibitors, and heart-related medications as prescribed. If you sometimes miss doses of these medicines, you may be able to join.
New York, New YorkAges 18–99 - NCT07444541RecruitingPhase 1/Phase 2
Study of ANO31905 plus chemo for CLDN18.2-positive pancreatic cancer
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
Phoenix, ArizonaAges 18 years+ - NCT02971358Recruiting
Surgery for very high-risk or limited-spread prostate cancer
This trial looks at how safe and how well early prostate surgery works for men with newly diagnosed very high-risk prostate cancer or a limited number of metastases (cancer spread). It may help some people live longer and control the cancer, but eligibility is very specific.
ViennaAges 18–75 - NCT03579836RecruitingPhase 1/Phase 2
Test BEY1107 plus gemcitabine for pancreatic cancer
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
SeoulAges 20–80
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,883 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.